INDIVIOR PHARMACEUTICALS INC (INDV) Stock Fundamental Analysis

NASDAQ:INDV • US45579U1097

34.58 USD
+0.82 (+2.43%)
At close: Feb 13, 2026
34.8449 USD
+0.26 (+0.77%)
After Hours: 2/13/2026, 8:17:28 PM
Overview Stock Chart Technical Analysis Fundamental Analysis Analyst Ratings Earnings Estimates Financials Ownership News
Fundamental Rating

5

Taking everything into account, INDV scores 5 out of 10 in our fundamental rating. INDV was compared to 191 industry peers in the Pharmaceuticals industry. INDV scores excellent on profitability, but there are some minor concerns on its financial health. A decent growth rate in combination with a cheap valuation! Better keep an eye on INDV.


Dividend Valuation Growth Profitability Health

7

1. Profitability

1.1 Basic Checks

  • INDV had positive earnings in the past year.
  • INDV had a positive operating cash flow in the past year.
  • In multiple years INDV reported negative net income over the last 5 years.
  • In multiple years INDV reported negative operating cash flow during the last 5 years.
INDV Yearly Net Income VS EBIT VS OCF VS FCFINDV Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 200M -200M 400M

1.2 Ratios

  • Looking at the Return On Assets, with a value of 8.62%, INDV belongs to the top of the industry, outperforming 89.53% of the companies in the same industry.
  • With an excellent Return On Invested Capital value of 50.62%, INDV belongs to the best of the industry, outperforming 100.00% of the companies in the same industry.
  • Measured over the past 3 years, the Average Return On Invested Capital for INDV is significantly above the industry average of 12.64%.
  • The 3 year average ROIC (43.06%) for INDV is below the current ROIC(50.62%), indicating increased profibility in the last year.
Industry RankSector Rank
ROA 8.62%
ROE N/A
ROIC 50.62%
ROA(3y)-3.2%
ROA(5y)-1.62%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)43.06%
ROIC(5y)30.49%
INDV Yearly ROA, ROE, ROICINDV Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 100 -100 200 300 400

1.3 Margins

  • The Profit Margin of INDV (10.34%) is better than 84.29% of its industry peers.
  • In the last couple of years the Profit Margin of INDV has declined.
  • INDV has a Operating Margin of 24.49%. This is amongst the best in the industry. INDV outperforms 91.62% of its industry peers.
  • INDV's Operating Margin has been stable in the last couple of years.
  • INDV has a better Gross Margin (85.51%) than 88.48% of its industry peers.
  • In the last couple of years the Gross Margin of INDV has remained more or less at the same level.
Industry RankSector Rank
OM 24.49%
PM (TTM) 10.34%
GM 85.51%
OM growth 3Y-2.47%
OM growth 5Y-1.25%
PM growth 3Y-81.34%
PM growth 5Y-60.3%
GM growth 3Y0.52%
GM growth 5Y0.74%
INDV Yearly Profit, Operating, Gross MarginsINDV Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 20 -20 40 60 80

More info and screens

ROAROEROICOperating and Profit MarginShow most profitable peers

4

2. Health

2.1 Basic Checks

  • INDV has a Return on Invested Capital (ROIC), which is well above the Cost of Capital (WACC), which means it is creating value.
  • Compared to 1 year ago, INDV has less shares outstanding
  • Compared to 5 years ago, INDV has less shares outstanding
  • The debt/assets ratio for INDV is higher compared to a year ago.
INDV Yearly Shares OutstandingINDV Yearly Shares OutstandingYearly Shares Outstanding 2016 2017 2018 2019 2020 2021 2022 2023 2024 50M 100M
INDV Yearly Total Debt VS Total AssetsINDV Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2016 2017 2018 2019 2020 2021 2022 2023 2024 500M 1B 1.5B

2.2 Solvency

  • An Altman-Z score of 2.72 indicates that INDV is not a great score, but indicates only limited risk for bankruptcy at the moment.
  • INDV has a better Altman-Z score (2.72) than 67.02% of its industry peers.
  • The Debt to FCF ratio of INDV is 2.68, which is a good value as it means it would take INDV, 2.68 years of fcf income to pay off all of its debts.
  • INDV has a Debt to FCF ratio of 2.68. This is amongst the best in the industry. INDV outperforms 92.67% of its industry peers.
Industry RankSector Rank
Debt/Equity N/A
Debt/FCF 2.68
Altman-Z 2.72
ROIC/WACC5.34
WACC9.48%
INDV Yearly LT Debt VS Equity VS FCFINDV Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 200M -200M 400M

2.3 Liquidity

  • INDV has a Current Ratio of 0.96. This is a bad value and indicates that INDV is not financially healthy enough and could expect problems in meeting its short term obligations.
  • INDV has a Current ratio of 0.96. This is amonst the worse of the industry: INDV underperforms 86.39% of its industry peers.
  • INDV has a Quick Ratio of 0.96. This is a bad value and indicates that INDV is not financially healthy enough and could expect problems in meeting its short term obligations.
  • INDV has a worse Quick ratio (0.79) than 82.72% of its industry peers.
Industry RankSector Rank
Current Ratio 0.96
Quick Ratio 0.79
INDV Yearly Current Assets VS Current LiabilitesINDV Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2016 2017 2018 2019 2020 2021 2022 2023 2024 500M 1B

More info and screens

WACCDebt/EquityHow to determine the health of a companyAltman-Z scoreShow peers with great health

5

3. Growth

3.1 Past

  • INDV shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 256.36%, which is quite impressive.
  • INDV shows a very negative growth in Earnings Per Share. Measured over the last years, the EPS has been decreasing by -53.19% yearly.
  • Looking at the last year, INDV shows a decrease in Revenue. The Revenue has decreased by -0.25% in the last year.
  • INDV shows quite a strong growth in Revenue. Measured over the last years, the Revenue has been growing by 8.64% yearly.
EPS 1Y (TTM)256.36%
EPS 3Y-75.32%
EPS 5Y-53.19%
EPS Q2Q%33.33%
Revenue 1Y (TTM)-0.25%
Revenue growth 3Y14.52%
Revenue growth 5Y8.64%
Sales Q2Q%2.28%

3.2 Future

  • The Earnings Per Share is expected to grow by 37.61% on average over the next years. This is a very strong growth
  • INDV is expected to show a small growth in Revenue. In the coming years, the Revenue will grow by 1.36% yearly.
EPS Next Y440.8%
EPS Next 2Y161.63%
EPS Next 3Y95.81%
EPS Next 5Y37.61%
Revenue Next Year3.67%
Revenue Next 2Y-0.17%
Revenue Next 3Y1.6%
Revenue Next 5Y1.36%

3.3 Evolution

  • When comparing the EPS growth rate of the last years to the growth rate of the upcoming years, we see that the growth is accelerating.
  • The Revenue growth rate is decreasing: in the next years the growth will be less than in the last years.
INDV Yearly Revenue VS EstimatesINDV Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 200M 400M 600M 800M 1B
INDV Yearly EPS VS EstimatesINDV Yearly EPS VS EstimatesYearly EPS VS Estimates 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 0 1 2 3

More info and screens

Find the best growth stocksShow best growing peers

8

4. Valuation

4.1 Price/Earnings Ratio

  • With a Price/Earnings ratio of 17.64, INDV is valued on the expensive side.
  • 85.86% of the companies in the same industry are more expensive than INDV, based on the Price/Earnings ratio.
  • When comparing the Price/Earnings ratio of INDV to the average of the S&P500 Index (26.68), we can say INDV is valued slightly cheaper.
  • A Price/Forward Earnings ratio of 11.48 indicates a reasonable valuation of INDV.
  • 86.91% of the companies in the same industry are more expensive than INDV, based on the Price/Forward Earnings ratio.
  • INDV's Price/Forward Earnings ratio indicates a rather cheap valuation when compared to the S&P500 average which is at 28.06.
Industry RankSector Rank
PE 17.64
Fwd PE 11.48
INDV Price Earnings VS Forward Price EarningsINDV Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 10 20 30

4.2 Price Multiples

  • Based on the Enterprise Value to EBITDA ratio, INDV is valued cheaper than 84.29% of the companies in the same industry.
  • 80.10% of the companies in the same industry are more expensive than INDV, based on the Price/Free Cash Flow ratio.
Industry RankSector Rank
P/FCF 35.98
EV/EBITDA 13.32
INDV Per share dataINDV EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 2 4 6 8

4.3 Compensation for Growth

  • The low PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates a rather cheap valuation of the company.
  • INDV has a very decent profitability rating, which may justify a higher PE ratio.
  • A more expensive valuation may be justified as INDV's earnings are expected to grow with 95.81% in the coming years.
PEG (NY)0.04
PEG (5Y)N/A
EPS Next 2Y161.63%
EPS Next 3Y95.81%

More info and screens

Price/EarningsPrice/FCFFCF per shareEV/EBITDAPEG RATIOShow best valued peers

0

5. Dividend

5.1 Amount

  • INDV does not give a dividend.
Industry RankSector Rank
Dividend Yield 0%

More info and screens

Find the best dividend stocksShow peers with best dividend

INDIVIOR PHARMACEUTICALS INC

NASDAQ:INDV (2/13/2026, 8:17:28 PM)

After market: 34.8449 +0.26 (+0.77%)

34.58

+0.82 (+2.43%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryPharmaceuticals
Earnings (Last)10-30
Earnings (Next)02-26
Inst Owners92.33%
Inst Owner Change-94.62%
Ins Owners3.78%
Ins Owner Change31.01%
Market Cap4.32B
Revenue(TTM)1.18B
Net Income(TTM)122.00M
Analysts84.62
Price Target46.48 (34.41%)
Short Float %9.74%
Short Ratio4.72
Dividend
Industry RankSector Rank
Dividend Yield 0%
Yearly DividendN/A
Dividend Growth(5Y)N/A
DP0%
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)81.89%
Min EPS beat(2)71.47%
Max EPS beat(2)92.31%
EPS beat(4)4
Avg EPS beat(4)70.49%
Min EPS beat(4)45.92%
Max EPS beat(4)92.31%
EPS beat(8)6
Avg EPS beat(8)12.14%
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)2
Avg Revenue beat(2)19.31%
Min Revenue beat(2)17.53%
Max Revenue beat(2)21.1%
Revenue beat(4)4
Avg Revenue beat(4)14.97%
Min Revenue beat(4)8.6%
Max Revenue beat(4)21.1%
Revenue beat(8)5
Avg Revenue beat(8)7.48%
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)20.38%
PT rev (3m)212.41%
EPS NQ rev (1m)0%
EPS NQ rev (3m)N/A
EPS NY rev (1m)0.43%
EPS NY rev (3m)79.73%
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)0%
Revenue NY rev (3m)12.81%
Valuation
Industry RankSector Rank
PE 17.64
Fwd PE 11.48
P/S 3.66
P/FCF 35.98
P/OCF 23.99
P/B N/A
P/tB N/A
EV/EBITDA 13.32
EPS(TTM)1.96
EY5.67%
EPS(NY)3.01
Fwd EY8.71%
FCF(TTM)0.96
FCFY2.78%
OCF(TTM)1.44
OCFY4.17%
SpS9.45
BVpS-1.66
TBVpS-1.67
PEG (NY)0.04
PEG (5Y)N/A
Graham NumberN/A
Profitability
Industry RankSector Rank
ROA 8.62%
ROE N/A
ROCE 64.08%
ROIC 50.62%
ROICexc 3805.17%
ROICexgc 5707.75%
OM 24.49%
PM (TTM) 10.34%
GM 85.51%
FCFM 10.17%
ROA(3y)-3.2%
ROA(5y)-1.62%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)43.06%
ROIC(5y)30.49%
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)54.5%
ROCE(5y)38.6%
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3Y-2.47%
OM growth 5Y-1.25%
PM growth 3Y-81.34%
PM growth 5Y-60.3%
GM growth 3Y0.52%
GM growth 5Y0.74%
F-Score8
Asset Turnover0.83
Health
Industry RankSector Rank
Debt/Equity N/A
Debt/FCF 2.68
Debt/EBITDA 0.97
Cap/Depr 230.77%
Cap/Sales 5.08%
Interest Coverage 250
Cash Conversion 57.14%
Profit Quality 98.36%
Current Ratio 0.96
Quick Ratio 0.79
Altman-Z 2.72
F-Score8
WACC9.48%
ROIC/WACC5.34
Cap/Depr(3y)163.83%
Cap/Depr(5y)132.28%
Cap/Sales(3y)2.67%
Cap/Sales(5y)2.59%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)256.36%
EPS 3Y-75.32%
EPS 5Y-53.19%
EPS Q2Q%33.33%
EPS Next Y440.8%
EPS Next 2Y161.63%
EPS Next 3Y95.81%
EPS Next 5Y37.61%
Revenue 1Y (TTM)-0.25%
Revenue growth 3Y14.52%
Revenue growth 5Y8.64%
Sales Q2Q%2.28%
Revenue Next Year3.67%
Revenue Next 2Y-0.17%
Revenue Next 3Y1.6%
Revenue Next 5Y1.36%
EBIT growth 1Y8.24%
EBIT growth 3Y11.69%
EBIT growth 5Y7.28%
EBIT Next Year1050.98%
EBIT Next 3Y148.27%
EBIT Next 5Y64.69%
FCF growth 1Y236.36%
FCF growth 3Y-74.97%
FCF growth 5Y-48.94%
OCF growth 1Y446.15%
OCF growth 3Y-53.28%
OCF growth 5Y-24.93%

INDIVIOR PHARMACEUTICALS INC / INDV FAQ

What is the fundamental rating for INDV stock?

ChartMill assigns a fundamental rating of 5 / 10 to INDV.


What is the valuation status of INDIVIOR PHARMACEUTICALS INC (INDV) stock?

ChartMill assigns a valuation rating of 8 / 10 to INDIVIOR PHARMACEUTICALS INC (INDV). This can be considered as Undervalued.


What is the profitability of INDV stock?

INDIVIOR PHARMACEUTICALS INC (INDV) has a profitability rating of 7 / 10.


How financially healthy is INDIVIOR PHARMACEUTICALS INC?

The financial health rating of INDIVIOR PHARMACEUTICALS INC (INDV) is 4 / 10.


Is the dividend of INDIVIOR PHARMACEUTICALS INC sustainable?

The dividend rating of INDIVIOR PHARMACEUTICALS INC (INDV) is 0 / 10 and the dividend payout ratio is 0%.